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Background: Leucopenia or neutropenia during chemotherapy predicts better survival in several cancers. We
aimed to assess whether leucopenia could be a biological measure of treatment and a marker of efficacy in
advanced nasopharyngeal carcinoma (ANPC).
Methods: We retrospectively analyzed 3826 patients with ANPC who received chemoradiotherapy. Leucopenia
was categorised on the basis of worst grade during treatment according to the National Cancer Institute Common
Toxicity Criteria version 4.0: no leucopenia (grade 0), mild leucopenia (grade 1–2), and severe leucopenia (grade
3–4). Associations between leucopenia and survival were estimated by Cox proportional hazards model.
Results: Of the 3826 patients, 2511 (65.6 %) developed mild leucopenia (grade 1–2) and 807 (21.1 %) developed
severe leucopenia (grade 3–4) during treatment; 508 (13.3 %) did not. A multivariate Cox model that included
leucopenia determined that the hazard ratios (HR) of death for patients with mild and severe leucopenia were 0.69
[95 % confidence interval (95 %CI) 0.56-0.85, p < 0.001] and 0.75 (95 %CI 0.59-0.95, p = 0.019), respectively; the HR
of distant metastasis for patients with mild and severe leucopenia were 0.77 (95 %CI 0.61-0.96, p = 0.023) and 0.99
(95 %CI 0.77-1.29, p = 0.995), respectively. Leucopenia had no effect on locoregional relapse.
Conclusions: Our results indicate that mild leucopenia during chemoradiotherapy is associated with improved
overall survival and distant metastasis–free survival in ANPC. Mild leucopenia may indicate appropriate dosage of
chemotherapy. We can identify the patients who may benefit from chemotherapy if they experienced leucopenia
during the treatment. Prospective trials are required to assess whether dosing adjustments based on leucopenia
may improve chemotherapy efficacy.
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Nasopharyngeal carcinoma (NPC) is a distinct type of
head and neck cancer. The incidence rate is as high as
20–30 per 100,000 populations in endemic areas of
southern China and Southeast Asia [1–3]. Radiotherapy
(RT) is the primary treatment, plus chemotherapy when
needed according to clinical stage. With the develop-
ment of diagnostic imaging, chemotherapy regimens,
targeted drugs, and radiotherapeutic techniques, espe-
cially the application of IMRT (Intensity Modulated* Correspondence: xiefy0758@sina.com
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unless otherwise stated.Radiation Therapy), survival of NPC has improved sig-
nificantly [4–6]. However, 10–20 % of patients with ad-
vanced NPC (ANPC) develop distant metastasis after
radical chemoradiotherapy, rendering distant metastases
the main reason for treatment failure. To reduce the oc-
currence of distant metastasis, different timings of
chemotherapy is recommended for ANPC according to
NCCN (National Comprehensive Cancer Network)
guidelines [7]. In 2014 version of NCCN guidelines , the
categories of evidence for induction or adjuvant chemo-
therapy of NPC has changed [7]. Category of induction
chemotherapy of NPC changed from category 2A to cat-
egory 3. Category of adjuvant chemotherapy “cisplatin +
RT followed by cisplatin/5-FU changed from category 1
to category 2A and “cisplatin + RT followed by carbopla-
tin/5-FU changed from category 2A to category 2B.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of cytotoxic drugs and could be a biological meas-
ure of drug activity and might predict treatment efficacy
[8, 9]. Leucopenia or neutropenia during treatment is a
common phenomenon of bone marrow suppression.
Some studies reported that leucopenia or neutropenia is
a prognostic factor predicting better clinical outcome in
several solid tumors, e.g., breast cancer [10–12], colorec-
tal cancer [13, 14], advanced gastric cancer [15–17], lung
cancer [18–20], and Hodgkin’s lymphoma [21]. Others
have reported different results [22, 23]. However, the pre-
dictive (ie, estimation of the chance of benefit from
chemotherapy) or prognostic (ie, estimation of the chance
of survival) role of leucopenia in advanced nasopharyngeal
carcinoma have not been established.
We aimed to investigate the association between
leucopenia during treatment and survival of ANPC and
to provide evidences, through rigorous statistical analysis
of a large series of subjects with ANPC, of the utility of
leukocyte count as a surrogate marker of drug efficacy.
Methods
Patients and methods
We retrospectively collected 3939 newly diagnosed ANPC
patients from January 2005 to December 2010 treated
in the Nasopharyngeal Carcinoma Department of Sun
Yat-Sen University Cancer Center. 113 paitents were ex-
cluded owing to different reasons, abnormal liver function,
abnormal kidney function, unsatisfactory blood sugar con-
trol and so on. 3826 patients were involved in the study.
The Sun Yat-Sen University Cancer Center Institutional
Review Board (IRB) and ethics committee reviewed and
approved the study. The study was retrospective. Patient
records were anonymized and de-identified prior to
analysis.
Pretreatment evaluation included complete patient his-
tory, physical examination, hematology and biochemistry
profiles, nasopharynx and neck magnetic resonance im-
aging (MRI), chest radiography, abdominal ultrasound,
bone emission computed tomography (ECT), and chest or
abdomen computed tomography (CT) when necessary.
Treatment
The treatment strategy for all patients was based on Na-
tional Comprehensive Cancer Network Guidelines [24,
25]. All patients were treated with intensity-modulated
RT (IMRT) or conventional RT (CRT) with chemother-
apy; the radiation techniques and chemotherapy regi-
mens have been described previously [26, 27].
Laboratory measurements
We performed leukocyte and neutrophil counts for all
patients within two weeks before therapy and at least
once weekly during treatment. The most severe grade ofleucopenia was based on the lowest recorded leukocyte
count for a given patient between the first day of treat-
ment administration and 1 week after the end of treat-
ment, and was graded according to the National Cancer
Institute Common Toxicity Criteria version 4.0. Patients
were classified as having no leucopenia (grade 0), mild
leucopenia (grade 1–2), and severe leucopenia (grade 3–4).
Indications for using granulocyte colony–stimulating
factor (G-CSF) were not specified; it was generally used
in grade 3–4 or febrile leucopenia, and was not used
for prophylaxis.
Follow-up
Patients were regularly followed after RT until death or
their last follow-up appointment. Clinic visits were
scheduled every three months in the first three years,
every six months during the fourth to fifth years, and
once a year after the fifth year. Patients underwent phys-
ical examination and nasopharyngoscopy on each visit.
Nasopharynx and neck MRI, chest radiography, abdom-
inal ultrasound, and ECT were performed after RT or
according to clinical indications. The follow-up duration
was calculated from the first day of therapy to the day of
death or the day of last examination.
Statistical analysis
We estimated the following endpoints (interval to the
first defining event): overall survival (OS), locoregional
relapse–free survival (LRFS), and distant metastasis–free
survival (DMFS). Survival curves were estimated using
the Kaplan-Meier method and compared using the log-
rank test. Multivariate analyses were performed using the
Cox proportional hazards model. We used chi-square
tests and Kruskal–Wallis H tests to assess the statistical
significance of associations between categorical variables
and the three groups. All statistical tests were 2-tailed;
p < 0.05 was considered statistically significant. All tests
were conducted using IBM SPSS version 20.0.0 (IBM
Corporation, Armonk, NY, USA).
Results
Patient characteristics
Table 1 lists the patient characteristics. We studied 3826
patients (2873 male; 953 female). The median age at diag-
nosis for male patients was 46 years (range 20–84 years);
that for female patients was 44 years (range 20–76 years).
CRT and IMRT were administered to 2583 and 1243 pa-
tients, respectively. Induction chemotherapy (IC) was ad-
ministered to 1073 patients, concurrent chemotherapy
(CC) to 1291 patients, IC plus CC (IC + CC) to 1255 pa-
tients, and CC plus adjuvant chemotherapy (CC + AC)
to 207 patients. We administered <4 and ≥4 che-
motherapy cycles to 2364 (61.8 %) and 1462 (38.2 %)
patients, respectively. No significant differences were
Table 1 Patient characteristics according to grade of leucopenia
Variable All Absent leucopenia Mild leucopenia Severe leucopenia P value
Total 3826 508(13.3) 2511(65.6) 807(21.1)
Gender <0.001
male 2873(75.1) 421(82.9) 1936(77.1) 516(63.9)
female 953(24.9) 87(17.1) 575(22.9) 291(36.1)
Age(years) 0.105
<45 1982(51.8) 242(47.6) 1325(52.8) 415(51.4)
> = 45 1844(48.2) 266(52.4) 1186(47.2) 392(48.6)
Leukocyte count <0.001
= < 10 × 10^9/L 3448(90.1) 424(83.5) 2278(90.7) 746(92.4)
>10 × 10^9/L 378(9.9) 84(16.5) 233(9.3) 61(7.6)
Pathological type(WHO) 0.692
I 83(2.2) 11(2.2) 55(2.2) 17(2.1)
II 203(5.3) 23(4.5) 143(5.7) 37(4.6)
III 3540(92.5) 474(93.3) 2313(92.1) 753(93.3)
T-classification 0.720
T1 172(4.5) 22(4.3) 109(4.3) 41(5.1)
T2 272(7.1) 29(5.7) 185(7.4) 58(7.2)
T3 1871(48.9) 271(53.3) 1221(48.6) 379(47.0)
T4 1511(39.5) 186(36.6) 996(39.7) 329(40.8)
N-classification 0.09
N0 517(13.5) 86(16.9) 335(13.3) 96(11.9)
N1 1978(51.7) 252(49.6) 1313(52.3) 413(51.2)
N2 1043(27.3) 133(26.2) 680(27.1) 230(28.5)
N3 288(7.5) 37(7.3) 183(7.3) 68(8.4)
Clinical stage 0.222
III 2094(54.7) 295(58.1) 1369(54.5) 430(53.3)
IV 1732(45.3) 213(41.9) 1142(45.5) 377(46.7)
Radiotherapy 0.004
CRT 2583(67.5) 329(64.8) 1741(69.3) 513(63.6)
IMRT 1243(32.5) 179(35.2) 770(30.7) 294(36.4)
Chemotherapy <0.001
IC 1073(28.0) 198(39.0) 697(27.8) 178(22.1)
CC 1291(33.7) 202(39.8) 878(35.0) 211(26.1)
IC + CC 1255(32.8) 98(19.3) 804(32.0) 353(43.7)
CC + AC 207(5.4) 10(2.0) 132(5.3) 65(8.1)
Paclitaxel <0.001
NO 3029(79.2) 403(79.3) 2069(82.4) 557(69.0)
YES 797(20.8) 105(20.7) 442(17.6) 250(31.0)
Chemotherapy cycles <0.001
<4 2364(61.8) 400(78.7) 1575(62.7) 389(48.2)
> = 4 1462(38.2) 108(21.3) 936(37.3) 418(51.8)
Abbreviations: CRT: conventional radiotherapy; IMRT: intensity modulated radiation therapy; IC: Induction chemotherapy; CC: concurrent chemotherapy;
AC: adjuvant chemotherapy; WHO: world health organization
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clinical stage. There were significant differences in pre-
treatment leukocyte count, type of chemotherapy,
chemotherapy cycles, type of RT, sex, and paclitaxel use
(yes or no) in the compared groups (all p < 0.05). Pa-
tients who developed leucopenia during treatment had
lower pretreatment leukocyte counts (p < 0.001). More
female patients developed leucopenia (female vs. male,
90.1 % vs. 85.3 %, p < 0.001); patients using paclitaxel
were likely to develop severe leucopenia (31.4 % vs.
18.4 %, p < 0.001).
The median OS was 52.6 months (range 3.07–113.0
months); 10.9 % of patients (417/3826) developed locor-
egional relapse, 16.5 % (633/3826) developed distant me-
tastases, and 19.0 % (727/3826) died. The 5-year OS,
LRFS, and DMFS rates for the entire population were
80.70 %, 87.9 %, and 82.1 %, respectively.
During treatment, 2511 patients (65.6 %) developed
mild leucopenia (grade 1–2) and 807 patients (21.1 %)Table 2 Univariate analysis of survival for patients with ANPC
All population Cycles <4
Variable OS DMFS OS
Leucopenia
Mild VS Absent
HR(95 %CI) 0.70(0.57-0.86) 0.79(0.63-0.98) 0.73(0.57-
p 0.001 0.038 0.009
Severe VS Absent
HR(95 %CI) 0.77(0.60-0.97) 1.01(0.78-1.31) 0.86(0.63-
P 0.030 0.927 0.320
Mild VS Severe
HR(95%CI) 0.91(0.76-1.09) 0.77(0.64-0.93) 0.85(0.66-
p 0.314 0.007 0.191
Gender
HR(95 %CI) 0.62(0.51-0.75) 0.69(0.57-0.84) 0.63(0.50-
P <0.001 <0.001 <0.001
Age
HR(95 %CI) 1.84(1.59-2.14) 1.09(0.93-1.27) 1.93(1.59-
P <0.001 0.304 <0.001
T-classification
HR(95 %CI) 1.27(1.14-1.40) 1.09(0.99-1.22) 1.27(1.11-
P <0.001 0.092 0.001
N-classification
HR(95CI) 1.56(1.43-1.70) 1.65(1.50-1.81) 1.70(1.51-
P <0.001 <0.001 <0.001
Radiotherapy
HR(95 %CI) 0.80(0.68-0.94) 0.91(0.76-1.08) 0.88(0.70-
P 0.008 0.273 0.264
Abbreviations: OS: overall survival; DMFS: distant metastasis-free survival; HR: hazarddeveloped severe leucopenia (grade 3–4); the remaining
508 (13.3 %) did not develop leucopenia.
Survival analyses including leucopenia
Table 2 shows the univariate analysis of the baseline and
clinical characteristics as prognostic factors, including
leucopenia. Kaplan–Meier curves according to severity of
leucopenia showed that better OS and DMFS were pre-
dicted for patients with leucopenia and that leucopenia had
no significant effect on LRFS (Fig. 1). The 5-year OS rate in
patients with no leucopenia, mild leucopenia, and severe
leucopenia was 75.5 %, 81.9 %, and 80.5 %, respectively
(mild vs no leucopenia, p = 0.001; severe vs no leucopenia,
p = 0.03; mild vs severe, p = 0.314). The 5-year DMFS rate
in patients with no leucopenia, mild leucopenia, and severe
leucopenia was 79.7 %, 83.7 %, and 78.9 %, respectively
(mild vs. no leucopenia, p = 0.038; severe vs no leucopenia,
p = 0.927; mild vs severe, p = 0.007). The 5-year LRFS rate
in patients with no leucopenia, mild leucopenia, and severepopulation Cycles > =4 population
DMFS OS DMFS
0.92) 0.87(0.66-1.14) 0.56(0.38-0.86) 0.56(0.37-0.86)
0.309 0.007 0.008
1.16) 1.10(0.79-1.54) 0.59(0.38-0.90) 0.73(0.46-1.14)
0.554 0.016 0.166
1.08) 0.78(0.61-1.02) 0.98(0.75-1.28) 0.77(0.58-1.09)
0.069 0.887 0.058
0.79) 0.71(0.55-0.91) 0.61(0.45-0.84) 0.67(0.49-0.2)
0.007 0.002 0.015
2.34) 1.14(0.94-1.39) 1.73(1.36-2.19) 1.01(0.77-1.30)
0.191 <0.001 0.941
1.45) 1.11(0.96-1.27) 1.26(1.07-1.49) 1.08(0.91-1.27)
0.157 0.007 0.375
1.90) 1.75(1.54-1.97) 1.39(1.21-1.60) 1.52(1.32-1.76)
<0.001 <0.001 <0.001
1.10) 1.03(0.82-1.30) 0.69(0.54-0.89) 0.75(0.58-0.97)
0.764 0.005 0.030
ratio; CI: confidence interval; ANPC: advanced nasopharyngeal carcinoma
Fig. 1 Kaplan–Meier survival curves of (a) Overall Survival, (b)
Locoregional Relapse-free Survival, and (c) Distant Metastasis-free
Survival according to severity of leucopenia
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p > 0.05 for any two compared groups).
We performed multivariate analysis to investigate
whether leucopenia could be a marker of improved OS
and DMFS (Table 3). Leucopenia and other prognostic
factors, i.e., age, sex, T classification, N classification, patho-
logical type, type of chemotherapy, paclitaxel use, and type
of RT were included in the multivariate analysis, which de-
termined that leucopenia, sex, T classification, and N classi-
fication were independent prognostic factors for OS and
DMFS. Compared to patients without leucopenia, the haz-
ard ratios (HRs) of death for patients with mild and severe
leucopenia were 0.69 [95 % confidence interval (95 %CI)
0.56-0.85, p < 0.001] and 0.75 (95 %CI 0.59-0.95, p = 0.019),
respectively. The HR of distant metastasis for patients with
mild and severe leucopenia were 0.77 (95 %CI 0.61-0.96,
p = 0.023) and 0.99 (95 %CI 0.77-1.29, p = 0.995), respect-
ively. When we compared patients with mild leucopenia to
patients with severe leucopenia, the HRs of death and dis-
tant metastasis were 0.93 (95 %CI 0.77-1.11, p = 0.416) and
0.77 (95%CI 0.64-0.93, p = 0.006), respectively.
When pretreatment leukocyte count (≤10 × 109/L
vs. >10 × 109/L) was included in the Cox model, leu-
copenia remained significant for OS (mild leucopenia:
HR = 0.70, 95 %CI 0.57-0.86, p = 0.001; severe leuco-
penia: HR = 0.76, 95 %CI 0.59-0.97, p = 0.026) and DMFS
(mild leucopenia: HR = 0.77, 95 %CI 0.61-0.96, p = 0.023;
severe leucopenia: HR = 0.99, 95 %CI 0.77-1.30, p = 0.995).
Tables 2 and 3 depict the subgroup analysis results for
patients who received <4 and ≥4 chemotherapy cycles.
Mild and severe leucopenia tended to be associated with
improved survival in patients who received <4 or ≥4
chemotherapy cycles.
Discussion
In this study, we found that survival was improved in pa-
tients who developed leucopenia during chemoradiother-
apy for ANPC. Patients with mild leucopenia had better
OS and DMFS than those with severe leucopenia. Leuco-
penia was an independent prognostic factor for OS and
DMFS in patients who received <4 and ≥4 chemotherapy
cycles. This is the first instance that has been reported in
pretreated ANPC.
As far as we know, leucopenia or neutropenia indicates
that the chemotherapeutic agent dose is sufficient to cause
bone marrow suppression and an anti-tumor effect [8, 9].
The absence of leucopenia or neutropenia indicates an ab-
sent or weak biological effect of chemotherapy, likely indi-
cating that the dose is too low. On the other hand, severe
leucopenia may indicate overdosage. High-dose chemo-
therapy does not improve survival, and impairs patient
quality of life [28]. We speculate that moderate-dose
chemotherapy, as evidenced by moderate toxicity, is the
optimal treatment, correlating with better survival than
Table 3 Multivariate analysis of survival for patients with ANPC
All population Cycles <4 population Cycles > =4 population
Variable OS DMFS OS DMFS OS DMFS
Leucopenia
Mild VS Absent
HR(95 %CI)a 0.69(0.56-0.85) 0.77(0.61-0.96) 0.70(0.55-0.89) 0.88(0.63-1.23) 0.73(0.46-1.15) 0.61(0.40-0.94)
P <0.001 0.023 0.003 0.452 0.174 0.025
Severe VS Absent
HR(95 %CI)a 0.75(0.59-0.95) 0.99(0.77-1.29) 0.82(0.60-1.11) 0.79(0.61-1.03) 0.97(0.74-1.27) 0.84(0.53-1.32)
P 0.019 0.995 0.204 0.083 0.828 0.446
Mild VS Severe
HR(95 %CI)a 0.93(0.77-1.11) 0.77(0.64-0.93) 0.85(0.66-1.09) 0.90(0.68-1.19 0.71(0.46-1.07 0.73(0.56-0.96)
P 0.416 0.006 0.204 0.469 0.108 0.026
Gender
HR(95 %CI) 0.67(0.55-0.81) 0.70(0.58-0.86) 0.66(0.52-0.84) 0.73(0.57-0.93) 0.66(0.48-0.91) 0.68(0.49-0.94)
P <0.001 <0.001 0.001 0.013 0.010 0.019
Age
HR(95 %CI) 1.82(1.57-2.12) 1.05(0.89-1.23) 1.88(1.55-2.28) 1.09(0.89-1.34 1.71(1.34-2.17) 1.03(0.81-1.33)
P <0.001 0.532 <0.001 0.367 <0.001 0.783
T-classification
HR(95 %CI) 1.49(1.35-1.66) 1.33(1.19-1.47) 1.51(1.33-1.72) 1.36(1.19-1.56) 1.49(1.26-1.76) 1.27(1.08-1.51)
P <0.001 <0.001 <0.001 <0.001 <0.001 0.005
N-classification
HR(95CI) 1.77(1.62-1.93) 1.78(1.62-1.97) 1.92(1.71-2.16) 1.92(1.68-2.18) 1.56(1.35-1.80) 1.63(1.40-1.90)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Abbreviations: OS: overall survival; DMFS: distant metastasis-free survival; HR: hazard ratio; CI: confidence interval; ANPC: advanced nasopharyngeal carcinoma
aAdjusted for age (<45 and ≥45 years old), sex, T classification (T1/T2/T3/T4), N classification (N0/N1/N2/N3), pathological type, type of radiotherapy, type of
chemotherapy, and paclitaxel use
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tients who received level II doses (65-84 % of the pre-
scribed dose) had longer disease-free survival (DFS) and
OS than patients who received higher (level I: >85 % of
the prescribed dose) or lower (level III: <65 % of the pre-
scribed dose) doses (p = 0.07, p = 0.03, respectively). Add-
itionally, Brunetto et al. reported that there was no
difference in OS for patients whose dose had been re-
duced compared to patients whose dose had been main-
tained [30]. Nakatat al. [17] and Shitara et al. [15] both
found that patients with mild neutropenia had better out-
comes than those with severe neutropenia; others have re-
ported that patients who developed grade 2–3 leucopenia
or neutropenia had significantly better prognosis than
those with grade 4 leucopenia or neutropenia [16, 17, 31].
Our results agree with these results. In other words, mild
leucopenia or neutropenia might be a barometer of the
appropriate chemotherapeutic dosage to obtain sufficient
anti-tumor effect in a patient, leading to improved clinical
outcome; however, severe leucopenia or neutropenia
might be a marker of overdosage and suboptimal survival.However, there are differing findings: Kim et al. [22]
reported that neutropenia was not a significant prognos-
tic indicator of improved progression-free survival and
OS (p = 0.180, p = 0.698, respectively) in stage I-IIIB
breast cancer. Kumpulainen et al. [23] drew a wholly dif-
ferent conclusion, where the 10-year DFS in FIGO
(International Federation of Obstetrics and Gynecology)
stage IC-IV disease was 45 % in patients with lower
leukocyte counts (<2.5 × 109/L) and 66 % in patients
with higher leukocyte counts (≥2.5 × 109/L) (p < 0.05).
The probable reason is that the different disease stages
might obscure the impact of leucopenia. Most studies
and ours studied patients with advanced-stage disease.
Several reports have stated that pretreatment high
leukocyte or neutrophil count might be a poor prognos-
tic indicator and that leucopenia or neutropenia are less
likely to occur during treatment [32, 33]. However, in
our multivariate analysis, which included this factor,
leucopenia remained significant for OS and DMFS.
Due to the retrospective nature of our study, there are
some limitations. First, the chemotherapy regimens and
Su et al. BMC Cancer  (2015) 15:429 Page 7 of 8dose varied. Second, patients were identified from 2005 to
2010, and the normal range of hematological profiles may
have varied. Third, although G-CSF was not used for
prophylaxis, it would nevertheless affect the severity of
leucopenia. Fourth, we only analyzed leucopenia, a sign of
myelosuppression. Taking hemoglobin and platelet inhib-
ition into account might reflect the relationship between
myelosuppression and prognosis more accurately.
Conclusions
Leucopenia during chemoradiotherapy of ANPC is
strongly associated with better OS and DMFS; mild
leucopenia indicates better survival than severe leuco-
penia. This may indicate that mild leucopenia is a surro-
gate marker for adequate chemotherapeutic dose. We
can identify the patients who may benefit from chemo-
therapy if they experienced leucopenia during the treat-
ment. The chemotherapy dose should not only depend
on the body surface area, but also be based on its toxic
effects. Prospective trials are required to assess whether
dosing adjustments based on leucopenia may improve
chemotherapy efficacy.
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